Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06309017
Other study ID # 23-01243
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 10, 2024
Est. completion date April 2025

Study information

Verified date March 2024
Source NYU Langone Health
Contact Jennifer Katz, MD
Phone (855) 698-4232
Email Jennifer.katz@nyulangone.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to determine if improved risk stratification tools and interventions to mitigate malnutrition reduce postoperative risk in patients undergoing elective or emergent resection surgery for inflammatory bowel disease (IBD), and if adding immune modulation nutrition improves surgical outcomes. The primary objective is to assess whether preoperative malnutrition screening and intervention minimize postoperative complications. The secondary objective is to evaluate whether immune modulation nutrition in the peri-operative period decreases length of stay and major complications.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date April 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Able and willing to provide written informed consent 2. Aged 18 years of age or older 3. Confirmed diagnosis of inflammatory bowel disease 4. Scheduled for disease-related intestinal resection at NYU Langone Health Exclusion Criteria: 1. No current diagnosis of inflammatory bowel disease 2. Age less than 18 3. Not proficient (able to read and answer questions) in English

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Nutrition specialist
Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
Dietary Supplement:
Ensure Surgery Immunonutrition shakes
All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.

Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of hospital stay From the time the patient is admitted at hospital for surgery until the patient is discharged. Up to 30 days post-surgery
Primary Proportion of patients who experienced postoperative major complications Major complications include infection, bleeding (requiring blood transfusion or requiring intervention), cardiac event (myocardial infarction, arrhythmia, and cardiac arrest), stroke, acute kidney injury (increase in serum creatinine of =0.3 mg/dL from baseline or =1.5 times baseline), venous thromboembolism, reoperation, readmission, and need for ICU-level care. The outcome measure will be obtained from the electronic health record (EHR). Visit 3 (30 days post-surgery)
Secondary Proportion of patients who participated in a nutritional intervention program before surgery Visit 3 (30 days post-surgery)
Secondary Proportion of patients who participated in a nutritional intervention program after surgery Visit 3 (30 days post-surgery)
Secondary Number of nutritional shakes completed Visit 3 (30 days post-surgery)
Secondary Percentage of nutritional shakes completed overall Visit 3 (30 days post-surgery)
Secondary Percentage of nutritional shakes completed pre-surgery Subject will be called the day prior to surgery to determine the number of shakes consumed by patient. One day prior to surgery
Secondary Percentage of nutritional shakes completed post-surgery One week after surgery, a phone call will follow to determine how many shakes subject consumed. One week post surgery
Secondary Proportion of patients who experienced any postoperative complications Visit 3 (30 days post-surgery)
Secondary Proportion of patients with 30 day readmission Up to 30 days post-surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02874365 - Intestinal Stem Cells Characterization N/A